SecBot SecBot

LQDA

Liquidia Corp
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001819576 Biotech & Drug Discovery
$42.65 +2.96 (+7.46%)
Oct 23 4:00 PM ET · prev $39.69
Market cap
$3.6B
Mid cap
Consensus
Buy
73% Buy or better · 15 analysts
Median target
$56.50
+32% · range $33.00–70.00
Next earnings
Nov 10
in 15 days · EPS est. $0.98
1 year
+87.4%
from $22.76 · Oct 27
30 days
−42.1%
from $73.67
52-week range
$22.45–91.03
−53% from high · low Oct 29
Avg volume 20D
7.39M
Sep 30 spike 22.95M
Short interest
🔒 Subscribers only
Insider net
−$34.8M
0 buyers · 12 sellers · since Jul 23
New fund stakes
7
Q2 2026 13F · 0 exits
Reddit crowd
61°
Warm · 5 mentions this week
SecBot read MIXED 11 reports · 90 days
Balance 2 bearish · 3 bullish · 1 mixed · 5 neutral oldest → newest, height = score
Avg score ·High conf. 8/11 ·Next Earnings date, Nov 10, 2026
Strongest MIXED Liquidia entered into a global settlement with United Therapeutics (UTC) resolving all six pending lawsuits…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    12 insiders sold $34.8M.

  • InstitutionsBULLISH

    Q2 2026: 50 added (7 new), 17 trimmed or exited. Largest new: Fuller & Thaler Asset Management, $96.4M, American Century Companies $43.2M.

  • AnalystsBULLISH

    11 of 15 rate it Buy or better. Median target $56.50 (+32%).

  • EstimatesFALLING

    Current-quarter EPS estimate $1.105 → $0.976 over 90 days. 0 up, 1 down in 30 days.

  • TrendDOWNTREND

    24% below its 50-day average.

  • SocialQUIET

    Crowd 61° (warm) this week from 5 mentions: 2 bullish, 0 bearish. No setup call. Excludes 1 subscriber-only day.

Who's buying

13F· Q2 2026
7
new positions
0
exits
$238.2M
in new stakes
FundMoveSharesValue
BlackRock, Inc.ADD10,788,586$860.2M
STATE STREET CORPADD3,030,395$241.6M
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED1,940,364$154.7M
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED1,532,151$122.2M
D. E. Shaw & Co., Inc.ADD1,267,706$101.1M
FULLER & THALER ASSET MANAGEMENT, INC.NEW1,209,604$96.4M
FEDERATED HERMES, INC.ADD816,187$65.1M
MORGAN STANLEYADD658,441$52.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 73% rate it Buy or better
Strong Buy5Buy6Hold4Sell0Strong Sell0
12-month targets · 8 analysts

Price is inside the target range. Median implies +32%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 15, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Oct 14, 2026LifeSci Capital
UPGRADE
UPGRADEOutperform
Oct 14, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Oct 14, 2026Needham
MAINTAIN
MAINTAINBuy
Oct 14, 2026BTIG
UPGRADE
UPGRADEBuy
Oct 2, 2026Wells Fargo
DOWNGRADE
DOWNGRADEEqual-Weight

Insider ledger

Form 4
$0
bought · 0 insiders
$34.8M
sold · 12 insiders
DateInsiderTypeValue
Oct 12, 2026
Adair Jason
Chief Business Officer
SELL$207.9K
Oct 12, 2026
Boyle Dana
Chief Accounting Officer
SELL$167.8K
Oct 12, 2026
JEFFS ROGER
Chief Executive Officer
SELL$932.5K
Oct 12, 2026
Krepp Sarah
Chief Human Resource Officer
SELL$149.4K
Oct 12, 2026
Kaseta Michael
CFO and COO
SELL$539.4K
Oct 12, 2026
Khindri Sanjeev
Chief Development Officer
SELL$31.4K
Oct 12, 2026
Moomaw Scott
Chief Commercial Officer
SELL$252.4K
Oct 12, 2026
Saggar Rajeev
Chief Medical Officer
SELL$262.5K

Earnings setup

Estimates
Nov 10
reports in 15 days
$0.98
EPS estimate, this quarter
−12%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current FY$2.03$1.47–$3.09-41.0%$717.0M
Current Q$0.98$0.69–$1.24-2.7%$214.1M
Next FY$2.19$0.95–$4.00-65.1%$762.1M
Next Q-$0.28-$1.01–$0.76-123.7%$198.4M
Reddit mentions per day, 14 days
Crowd this week 61° Warm 2 bullish · 0 bearish
Mentions, 7 days 5 2 in posts · 3 in comments
Recent posts
r/wallstreetbets Neutral 3d ago
LQDA lawsuit gains
1 upvotes · 0 comments
r/thetagang Neutral 3d ago
1% Weekly Returns from Options Week 34 - Worst two weeks
36 upvotes · 37 comments
r/thetagang Neutral 11d ago
1% Weekly Returns from Options Week 33 - Crash Testing CSPs
31 upvotes · 55 comments
r/wallstreetbets Bullish 12d ago
$LQDA: Wall Street Priced In a Funeral. Instead, We Got $222.7M in Quarterly Sales and 12.6 MILLION Shares Short. 🚀🦍
1 upvotes · 0 comments
r/wallstreetbets Neutral 13d ago
How much will these LQDA $40 calls be worth tomorrow?
1 upvotes · 5 comments
Recent comments
r/wallstreetbets1d ago
Fresh comment, for subscribers
r/wallstreetbets Bullish 2d ago
They basically settled, key bull case is that the settlement removes the legal uncertainty and lets LQDA keep commercializing Yutrepia for PAH which is a huge market
r/wallstreetbets Bullish 2d ago
LQDA about to skyrocket
r/thetagang Neutral 3d ago
rough couple weeks for sure but its just part of the game when market goes against you. at least you still collected something even if its small, that 0.25% is better than nothing when retired your rule about not selling calls below assignment price is important, learned that the hard way myself. LQDA situation sounds annoying with low liquidity, hope you can dig out of it when vol come back
All social signals and their track records

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Sep 30, 2026Volatility PauseResumed
Sep 30, 2026Resumption ScheduledResumed
Sep 30, 2026Volatility PauseResumed
Sep 30, 2026Volatility PauseResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 15, 2026 Short interest report
🔒 Fresh data, subscribers only
Oct 13, 2026 SEC
Liquidia entered into a global settlement with United Therapeutics (UTC) resolving all six pending lawsuits, including…
8-K — Impact 7/10
Oct 13, 2026 SEC
Two Liquidia Corp insiders (Chief Business Officer and Chief Accounting Officer) sold a combined $376K in open-market…
CLUSTER — Impact 4/10
Oct 12, 2026 Insider
Adair Jason sold 7,301 shares
Chief Business Officer @ $28.48 ($207.9K)
Oct 12, 2026 Insider
Boyle Dana sold 5,892 shares
Chief Accounting Officer @ $28.48 ($167.8K)
Oct 12, 2026 Insider
JEFFS ROGER sold 32,744 shares
Chief Executive Officer @ $28.48 ($932.5K)
Sep 30, 2026 SEC
The District Court ruled that two of six patent claims asserted by United Therapeutics against Liquidia's YUTREPIA are…
8-K — Impact 7/10
Sep 3, 2026 Press
No summary provided
Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
LQDA Q3 2026 Earnings Before Market Open — 2026-11-10
Recent
Oct 15, 2026
Short interest
🔒 Fresh data, subscribers only
Oct 13, 2026
Press release
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
Fully resolves all six ongoing lawsuits between the companiesMaintains uninterrupted access to YUTREPIA® for patients with pulmonary arterial…
Sep 30, 2026
Trading halt
Halt Resumed: LQDA — trading resumed after LUDP (Volatility Trading Pause)
Halted 2026-09-30T17:47:37.000Z | Resumed 2026-09-30T17:52:37.000Z
Sep 30, 2026
Trading halt
Trading Halt: LQDA — LUDP (Volatility Trading Pause)
Liquidia Corporation Cmn Stk | Market: NASDAQ | Code: LUDP — Volatility Trading Pause
Sep 30, 2026
Trading halt
Halt Resumed: LQDA — trading resumed after T3 (News and Resumption Times)
Halted 2026-09-30T15:38:29.000Z | Resumed 2026-09-30T17:40:00.000Z

SecBot reports

43 filings · 2 press releases · 6 bullish · 13 bearish · 2 mixed · 22 neutral
All LQDA filing & press-release reports (45)